Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stifel Canada raised their FY2025 earnings estimates for shares of Cipher Pharmaceuticals in a research report issued to clients and investors on Tuesday, December 3rd. Stifel Canada analyst J. Keywood now forecasts that the company will earn $0.98 per share for the year, up from their prior estimate of $0.97. Stifel Canada has a "Strong-Buy" rating on the stock. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last announced its earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing analysts' consensus estimates of C$0.03 by C($0.02). The firm had revenue of C$14.15 million for the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%.
Several other equities research analysts have also recently commented on CPH. Stifel Nicolaus decreased their target price on Cipher Pharmaceuticals from C$19.00 to C$17.00 in a research note on Monday, November 11th. Leede Financial cut Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 13th.
Check Out Our Latest Report on CPH
Cipher Pharmaceuticals Trading Up 1.6 %
Cipher Pharmaceuticals stock traded up C$0.25 during trading hours on Friday, reaching C$16.00. 15,634 shares of the company's stock were exchanged, compared to its average volume of 47,578. The firm's 50 day simple moving average is C$15.42 and its 200 day simple moving average is C$13.02. Cipher Pharmaceuticals has a twelve month low of C$5.35 and a twelve month high of C$19.69. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of C$409.44 million, a PE ratio of 12.80 and a beta of 1.20.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
See Also
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
